TP 508
- Product Name
- TP 508
- CAS No.
- 121341-81-9
- Chemical Name
- TP 508
- Synonyms
- TP 508;L-Valine, L-alanylglycyl-L-tyrosyl-L-lysyl-L-prolyl-L-α-aspartyl-L-α-glutamylglycyl-L-lysyl-L-arginylglycyl-L-α-aspartyl-L-alanyl-L-cysteinyl-L-α-glutamylglycyl-L-α-aspartyl-L-serylglycylglycyl-L-prolyl-L-phenylalanyl-
- CBNumber
- CB61363881
- Molecular Formula
- C97H146N28O36S
- Formula Weight
- 2312.46
- MOL File
- 121341-81-9.mol
TP 508 Property
- Density
- 1.56±0.1 g/cm3(Predicted)
- InChIKey
- MOZAQZCGIKWACU-BRMVNBHNNA-N
N-Bromosuccinimide Price
- Product number
- CS-7065
- Product name
- TP508
- Packaging
- 1mg
- Price
- $144
- Updated
- 2021/12/16
- Product number
- CS-7065
- Product name
- TP508
- Packaging
- 5mg
- Price
- $576
- Updated
- 2021/12/16
TP 508 Chemical Properties,Usage,Production
Biological Activity
TP508 is a 23 amino acid non-proteolytic thrombin peptide representing part of the receptor binding domain of the thrombin molecule. It activates endothelial NO synthase (eNOS) and stimulates NO production in human endothelial cells. TP508 enables angiogenesis and tissue regeneration by activating endothelial cells and stem cells.
in vitro
TP508 (50 μg/mL; 24 hours; HCAEC) treatment reverses radiation-induced endothelial dysfunction (ED) and loss of NO signaling by attenuating the downregulation of eNOS expression. TP508 treatment is able to stimulate NO production in the irradiated cells.
TP508 mitigates effects of nuclear radiation on human endothelial cells in culture restoring endothelial NO production, tube formation and accelerating repair of radiation-induced DNA double-strand breaks (DSB).
TP508 acts as an antagonist for the effects of thrombin. TP508 peptide inhibits these thrombin-induced effects through a RGD and αvβ3-related mechanism.
Western Blot Analysis
| Primary human coronary artery endothelial cells (HCAEC) | |
| Concentration: | 50 μg/mL |
| Incubation Time: | 24 hours |
| Result: | Prevented the radiation-induced downregulation of eNOS. |
in vivo
TP508 (10 mg/kg; intravenous injection; male CD-1 mice) treatment mitigates radiation-induced endothelial cell damage, also significantly increases survival of CD-1 mice when injected 24 h after 8.5 Gy exposure. < /p>
| Animal Model: | Male CD-1 mice (12-15-week old) with γ irradiation |
| Dosage: | 10 mg/kg |
| Administration: | Intravenous injection |
| Result: | Mitigated radiation-induced endothelial cell damage, also significantly increased survival of CD-1 mice. |
TP 508 Preparation Products And Raw materials
Raw materials
Preparation Products
TP 508 Suppliers
- Tel
- 021-58955995
- Fax
- 609-228-5909
- sales@medchemexpress.cn
- Country
- United States
- ProdList
- 4861
- Advantage
- 58
- Tel
- info@creative-peptides.com
- Country
- United States
- ProdList
- 6083
- Advantage
- 56
- Tel
- 16314854226; +16314854226
- inquiry@bocsci.com
- Country
- United States
- ProdList
- 19741
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@medchemexpress.com
- Country
- United States
- ProdList
- 6398
- Advantage
- 58
View Lastest Price from TP 508 manufacturers
- Product
- TP508 121341-81-9
- Price
- US $20.00-9000.00/vial
- Min. Order
- 10vial
- Purity
- 99.99%
- Supply Ability
- 90000kit
- Release date
- 2023-08-24